Clinical benefits of inhaled ciclesonide for hospitalized patients with COVID-19 infection: a retrospective study

• Research
• Open Access
• 
  

• Kuan-Chih Kuo, 
• Chao-Hsien Chen, 
• Chieh-Jen Wang, 
• Jou-Chun Wu, 
• Hsin-Pei Chung, 
• Yen-Ting Chen, 
• Yen-Hsiang Tang, 
• Wen-Kuei Chang, 
• Chang-Yi Lin & 
• Chien-Liang Wu 

BMC Pulmonary Medicine volume 22, Article number: 368 (2022) 

• details

Abstract

Background

The successful management of patients infected with coronavirus disease 2019 (COVID-19) with inhaled ciclesonide has been reported, however few studies have investigated its application among hospitalized patients.

Methods

This retrospective cohort study enrolled all adult patients admitted to our hospital with confirmed COVID-19 infection from May to June 2021.

Validation of an overnight wireless high-resolution oximeter for the diagnosis of obstructive sleep apnea at home

• Article
• Open Access
• Published: 07 September 2022

Rosa Hasan, 

Pedro Rodrigues Genta, 

George do Lago Pinheiro, 

Michelle Louvaes Garcia, 

Paula Gobi Scudeller, 

Carlos Roberto Ribeiro de Carvalho & 

Geraldo Lorenzi-Filho 

Scientific Reports volume 12, Article number: 15136 (2022) 

• details

Abstract

Obstructive sleep apnea (OSA) is extremely common and has several consequences. However, most cases remain undiagnosed. One limitation is the lack of simple and validated methods for OSA diagnosis at home. The aim of this study was to validate a wireless high-resolution oximeter with a built-in accelerometer linked to a smartphone with automated cloud analysis (Biologix) that was compared with a home sleep test (HST, Apnea Link Air) performed on the same night. We recruited 670 patients out of a task force of 1013 patients with suspected OSA who were referred to our center for diagnosis.

Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies

• Short report
• Open Access
• 
  

• Timothy J. Craig, 
• Rafael H. Zaragoza-Urdaz, 
• H. Henry Li, 
• Ming Yu, 
• Hong Ren, 
• Salomé Juethner, 
• John Anderson on behalf of 
• the HELP and HELP OLE Study Investigators

Allergy, Asthma & Clinical Immunology volume 18, Article number: 85 (2022) 

• details

Abstract

Background

The COVID-19 pandemic has highlighted disparities in healthcare, particularly in the United States, even though disparities have existed since the organization of the modern healthcare system. Recruitment of patients from racial and ethnic minority groups is often minimal in phase 3 clinical trials, and is further exacerbated in the case of trials for rare diseases such as hereditary angioedema (HAE).

Chronic air pollution-induced subclinical airway inflammation and polygenic susceptibility

• Research
• Open Access
• 
  

• Sara Kress, 
• Claudia Wigmann, 
• Qi Zhao, 
• Christian Herder, 
• Michael J. Abramson, 
• Holger Schwender & 
• Tamara Schikowski 

Respiratory Research volume 23, Article number: 265 (2022) 

• details

Abstract

Background

Air pollutants can activate low-grade subclinical inflammation which further impairs respiratory health. We aimed to investigate the role of polygenic susceptibility to chronic air pollution-induced subclinical airway inflammation.

Methods

We used data from 296 women (69–79 years) enrolled in the population-based SALIA cohort (Study on the influence of Air pollution on Lung function, Inflammation and Aging). Biomarkers of airway inflammation were measured in induced-sputum samples at follow-up investigation in 2007–2010. Chronic air pollution exposures at residential addresses within 15 years prior to the biomarker assessments were used to estimate main environmental effects on subclinical airway inflammation.

Guidance for Administering Biologics for Severe Asthma and Allergic Conditions

Can Respir J. 2022; 2022: 9355606.
doi: 10.1155/2022/9355606
Delbert R. Dorscheid, 1 Jason K. Lee, 2 Warren Ramesh, 3 Mark Greenwald, 4 and Jaime Del Carpio 5

Abstract

Asthma is a common respiratory disorder in Canada for which biologics may be prescribed for poorly controlled illness. Treatment with biologics, however, is sometimes inappropriately discontinued due to misconceptions regarding their potential immunologic effects, and concerns surrounding their continued use in severe asthma during the COVID-19 pandemic continue to propagate. Biologics can still be administered in a majority of health and treatment conditions. With regard to cardiac-related issues such as hypertension or cardiovascular disease (CVD), there is no solid evidence that suggests biologics should be withheld, as the benefits of treatment outweigh the risks. Asthmatic patients on biologic treatment should also continue treatment if they have, or are currently being treated for, a respiratory infection, including COVID-19. Evidence also indicates the importance of maintaining asthma control to reduce the risk of severe COVID-19 infection.

Induction of natural IgE by glucocorticoids

Lim J, Lin EV, Hong JY, Vaidyanathan B, Erickson SA, Annicelli C, Medzhitov R. Induction of natural IgE by glucocorticoids. J Exp Med. 2022 Oct 3;219(10):e20220903. doi: 10.1084/jem.2022090

3.

IgE mediates allergic responses by coating mast cell or basophil surfaces and inducing degranulation upon binding a specific allergen. IgE can also be spontaneously produced in the absence of foreign allergens; yet the origin, regulation, and functions of such “natural” IgE still remain largely unknown. Here, we find that glucocorticoids enhance the production of IgE in B cells both in vivo and ex vivo without antigenic challenge. Such IgE production is promoted by B cell–intrinsic glucocorticoid receptor signaling that reinforces CD40 signaling and synergizes with the IL-4/STAT6 pathway. In addition, we found that rare B cells in the mesenteric lymph nodes are responsible for the production of glucocorticoid-inducible IgE.

Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial

• Research
• Open Access

• Peter Daley-Yates, 
• Brian Keppler, 
• Amanda Baines, 
• George Bardsley & 
• James Fingleton 

Respiratory Research volume 23, Article number: 258 (2022) 

Abstract

Background

Fluticasone furoate/vilanterol trifenatate (FF/VI) is an inhaled therapy for the treatment of asthma, with a prolonged duration of anti-inflammatory and bronchodilatory action. This study investigated the global metabolomic and lipidomic profile following treatment with FF/VI or placebo and assessed whether changes correlated with exhaled nitric oxide levels as a measure of airway inflammation.

Recent advances in vitamin D implications in chronic respiratory diseases

• Review
• Open Access
• 
  

• Mellissa Gaudet, 
• Maria Plesa, 
• Andrea Mogas, 
• Nour Jalaleddine, 
• Qutayba Hamid & 
• Saba Al Heialy 

Respiratory Research volume 23, Article number: 252 (2022) 

• details

Abstract

Chronic airway inflammatory and infectious respiratory diseases are the most common medical respiratory conditions, associated with significant morbidity and mortality. Vitamin D (1,25(OH)2D3) deficiency has been shown to be highly prevalent in patients with chronic airway inflammatory and infectious diseases, correlated with increased disease severity. It has been established that vitamin D modulates ongoing abnormal immune responses in chronic respiratory diseases and is shown to restrict bacterial and viral colonization into the lungs.